Education
About Us
Working with TipRanks
Follow Us
Armata Pharmaceuticals Inc (ARMP)
:ARMP
ARMP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.34 - $3.85
Previous CloseN/A
Volume48.90K
Average Volume (3M)15.76K
Market Cap
$52.83M
Enterprise Value$226.53M
Total Cash (Recent Filing)$13.52M
Total Debt (Recent Filing)$120.37M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 08, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding36,183,067
10 Day Avg. Volume24,825
30 Day Avg. Volume15,761
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.44
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap4.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.75
Enterprise Value/Ebitda-7.26
Forecast
1Y Price Target
$7.00Price Target Upside438.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Armata Pharmaceuticals News
PremiumCompany Announcements
Armata Pharmaceuticals Secures $10M Loan for Clinical Trials
PremiumCompany Announcements
Armata Pharmaceuticals Reports Positive Phase 2 Study Results
PremiumCompany Announcements
Armata Pharmaceuticals Announces CMO Departure Agreement
PremiumCompany Announcements
Armata Pharmaceuticals Extends Credit Agreement and CMO Departs---
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyThe overall data from the Phase 2 Tailwind clinical trial is encouraging, showing a trend towards efficacy for AP-PA02.
Safety ProfileAP-PA02 was generally safe and well tolerated, with any treatment emergent adverse events being mild and self-limiting.
Bears Say
Efficacy ComparisonAn efficacy analysis of each independent cohort demonstrated no significant difference between subjects treated with AP-PA02 and placebo when the study's planned statistical analysis plan was utilized.
Statistical SignificanceThe primary endpoint of the Phase 2 Tailwind clinical trial did not reach statistical significance, likely due to small numbers of subjects.
---
Ownership Overview
0.75% Insiders
1.07% Mutual Funds
0.57% Other Institutional Investors
96.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was $1.34 and its highest was $3.85 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is $52.83M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is May 08, 2025 which is in 34 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on Mar 20, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.35 by $0.12.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -0.38.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,183,067 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.35. Following the earnings report the stock price went down -10.945%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
---
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
---
ARMP Stock 12 Month Forecast
Average Price Target
$7.00
▲(438.46% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
PDS Biotechnology
―
Cue Biopharma
―
Aligos Therapeutics
―
Context Therapeutics
―
Best Analysts Covering ARMP
1 Year
1 Year Success Rate
11/28 ratings generated profit
1 Year Average Return
-6.17%
reiterated a buy rating 8 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 39.29% of your transactions generating a profit, with an average return of -6.17% per trade.
---